Annovis Bio's Phase III Study Shows Buntanetap Improves Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and Cognitive Function
Overview
Annovis Bio Inc. (NYSE: ANVS) has released new data from its Phase III study of buntanetap, a treatment aimed at neurodegenerative disorders like Parkinson's Disease (PD). The study reveals significant improvements in motor and non-motor functions, as well as cognitive abilities, among patients with early PD. Buntanetap demonstrated the ability to prevent cognitive decline across all enrolled patients, particularly those with mild dementia, where it outperformed the placebo group.
Buntanetap: Effects
- In patients diagnosed with PD for over three years, buntanetap effectively improved motor functions, as indicated by improvements in MDS-UPDRS Part II, Part III, and Total scores compared to baseline and placebo.
- The treatment also showed promise in patients with Postural Instability and Gait Difficulty (PIGD), a subgroup known for rapid disease progression.
Safety Profile of Buntanetap
- The safety profile of buntanetap was consistent across all participants, reinforcing its safety record from previous AD studies.
- These findings underscore Annovis Bio's commitment to advancing buntanetap into further studies to explore its symptomatic benefits and potential disease-modifying properties.
